Compare HFWA & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HFWA | COLL |
|---|---|---|
| Founded | 1927 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1997 | 2015 |
| Metric | HFWA | COLL |
|---|---|---|
| Price | $29.66 | $35.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $30.50 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 397.9K | 342.4K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | ★ 58.06 | N/A |
| EPS | ★ 0.48 | 0.40 |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | $45.85 | $8.01 |
| Revenue Next Year | $7.83 | N/A |
| P/E Ratio | ★ $61.54 | $90.20 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $21.32 | $29.70 |
| 52 Week High | $31.25 | $50.79 |
| Indicator | HFWA | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 48.27 | 45.76 |
| Support Level | $28.87 | $33.93 |
| Resistance Level | $30.92 | $35.76 |
| Average True Range (ATR) | 0.74 | 1.35 |
| MACD | -0.16 | -0.10 |
| Stochastic Oscillator | 21.06 | 21.89 |
Heritage Financial Corp is a bank holding company. The company, through its subsidiary, provides commercial lending and deposit relationships with small businesses and their owners in its market areas and attracts deposits from the general public. It accepts various deposit products, such as non-interest demand accounts, money market accounts, savings accounts, and certificates of deposit. Besides, the Bank also makes real estate construction loans, land development loans, and consumer loans, and originates first mortgage loans on residential properties mainly located in its market area. Geographically, all the business activity functions through the region of the United States.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.